Literature DB >> 23659946

The biopsy-proven benign thyroid nodule: is long-term follow-up necessary?

Sukhyung Lee1, Thomas S Skelton, Feibi Zheng, Katherine A Schwartz, Nancy D Perrier, Jeffrey E Lee, Roland L Bassett, Salmaan Ahmed, Savitri Krishnamurthy, Naifa L Busaidy, Elizabeth G Grubbs.   

Abstract

BACKGROUND: Thyroid nodules are common, and of those biopsied by fine-needle aspiration (FNA), the majority will be benign colloid nodules (BCN). Current guidelines suggest these BCN should be followed by ultrasonographic examination (US) every 3 years, with no endpoint specified. This study evaluated if long-term follow-up of benign thyroid nodules was associated with change in treatment or improvement in diagnosing a missed malignancy compared with short-term follow-up. STUDY
DESIGN: All patients with FNA-based diagnosis of BCN at our institution from 1998 to 2009 were identified. Patients observed after the diagnosis were divided into short-term follow-up (<3 years) and long-term follow-up (≥3 years). Rates of repeat FNA, thyroidectomy, and malignancy detection were compared.
RESULTS: Of 738 patients with BCN, 92 patients underwent thyroid resection after the initial US. Six hundred forty-six patients were observed, of which 366 returned for 1 or more follow-up US: 226 in the short-term group (median 13 months) and 140 in the long-term group (median 57 months). There were more follow-up US in long-term vs short-term (medians 4 vs 2, p < 0.01), more repeat FNAs in the long-term group (18 of 140 vs 8 of 226, p < 0.01); but no difference in interval thyroidectomies (13 of 140 vs 31 of 226, p = 0.25) or malignant final pathology (0 of 13 vs 2 of 31, p > 0.99). For all patients undergoing surgery, pathology was malignant in 2 of 136 (1.5%).
CONCLUSIONS: Long-term follow-up of patients with BCN is associated with increased repeat FNA and US without improvement in the malignancy detection rate. After 3 years of follow-up, consideration should be given to ceasing long-term routine follow-up of biopsy-proven BCN.
Copyright © 2013 American College of Surgeons. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23659946     DOI: 10.1016/j.jamcollsurg.2013.03.014

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  9 in total

1.  European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics.

Authors:  Ralf Paschke; Silvia Cantara; Anna Crescenzi; Barbara Jarzab; Thomas J Musholt; Manuel Sobrinho Simoes
Journal:  Eur Thyroid J       Date:  2017-05-19

2.  Malignancy risk of initially benign thyroid nodules: validation with various Thyroid Imaging Reporting and Data System guidelines.

Authors:  Su Min Ha; Jung Hwan Baek; Young Jun Choi; Sae Rom Chung; Tae Yon Sung; Tae Yong Kim; Jeong Hyun Lee
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

3.  Natural course of benign thyroid nodules.

Authors:  Kyung Won Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2013-06

4.  Prognosis of patients with benign thyroid nodules: a population-based study.

Authors:  Naykky Singh Ospina; Spyridoula Maraka; Ana Elena Espinosa de Ycaza; Juan P Brito; M Regina Castro; John C Morris; Victor M Montori
Journal:  Endocrine       Date:  2016-05-03       Impact factor: 3.633

5.  Response: natural course of cytologically benign thyroid nodules: observation of ultrasonographic changes (endocrinol metab 2013;28:110-8, dong jun lim et Al.).

Authors:  Dong Jun Lim; Ki Hyun Baek
Journal:  Endocrinol Metab (Seoul)       Date:  2013-09

6.  Thyrolipomas - Prevalence in Computed Tomography and Suggestions for Pragmatic Management.

Authors:  Johannes Gossner
Journal:  Pol J Radiol       Date:  2015-06-13

7.  Type 2 diabetes mellitus is more prevalent among patients with thyroid carcinoma and influences overall survival: a propensity score matching analysis.

Authors:  Tao Jiang; Guoliang Qiao; Xiao Zheng; Zhen Wen; Dongxue Zhang
Journal:  Oncotarget       Date:  2017-10-31

8.  Evaluation of the safety and efficacy of radiofrequency ablation for treating benign thyroid nodules.

Authors:  Xiaoyin Tang; Dan Cui; Jiachang Chi; Zhi Wang; Tao Wang; Bo Zhai; Ping Li
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

9.  FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.

Authors:  Elizabeth J de Koster; Dennis Vriens; Maarten O van Aken; Lioe-Ting Dijkhorst-Oei; Wim J G Oyen; Robin P Peeters; Abbey Schepers; Lioe-Fee de Geus-Oei; Wilbert B van den Hout
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-18       Impact factor: 10.057

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.